Daniela Impellizzeri1, Giuseppe Bruschetta1, Marika Cordaro1, Rosalia Crupi1, Rosalba Siracusa1, Emanuela Esposito1, Salvatore Cuzzocrea2,3. 1. Department of Biological and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, no 31, Messina, 98166, Italy. 2. Department of Biological and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, no 31, Messina, 98166, Italy. salvator@unime.it. 3. Manchester Biomedical Research Centre, Manchester Royal Infirmary, University of Manchester, Manchester, Oxford Rd, Manchester, M13 9WL, UK. salvator@unime.it.
The authors would like to issue an erratum for this article [1], and would like to declare the following competing interests which we inadvertently failed to include in our original publication. The authors would like to apologise for this omission.
Competing interests
Dr. Salvatore Cuzzocrea, researcher on the study team, is co-inventor on patent WO2013121449 A8 (Epitech Group SpA) which deals with compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines useable in the therapy of inflammatory diseases. Moreover, Dr. Cuzzocrea is also a co-inventor with Epitech group on the following patents:EP 2 821 083MI2014 A001495102015000067344No other authors have competing interests.